Status:

COMPLETED

A Research Study of How NNC0174-0833 Behaves in Japanese and Caucasian Volunteers Who Are Normal Weight, Overweight or With Obesity

Lead Sponsor:

Novo Nordisk A/S

Conditions:

Obesity

Overweight

Eligibility:

MALE

Phase:

PHASE1

Brief Summary

The aim of this study is to look at how the study medicine behaves in the participant's body and how it is removed from the participant's body. The study compares Japanese and Caucasian people who are...

Eligibility Criteria

Inclusion

  • Male, aged 18-55 years (both inclusive) at the time of signing informed consent.
  • For Japanese subjects, both parents of Japanese descent and both paternal and maternal grandparents of Japanese descent.
  • For Caucasian subjects, self-reported European descent or white Latin-American descent.
  • Body mass index (BMI) between 20.0 and 39.9 kg/m\^2 (both inclusive) at screening. Overweight should be due to excess adipose tissue, as judged by the investigator.
  • Body weight between 60 and 110 kg (both inclusive) at screening

Exclusion

  • Male subject who is not surgically sterilised (vasectomy) and is sexually active (with female partner\[s\] of childbearing potential), who is not using a highly effective method of contraception (such as condom with spermicide) combined with a highly effective method of contraception for their non-pregnant female partner(s) (Pearl Index less than 1%), or intend to donate sperm in the period from screening until 3 months following administration of the investigational medical product.
  • Any disorder which in the investigator's opinion might jeopardise subject's safety or compliance with the protocol.

Key Trial Info

Start Date :

January 7 2019

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 4 2019

Estimated Enrollment :

66 Patients enrolled

Trial Details

Trial ID

NCT03787225

Start Date

January 7 2019

End Date

June 4 2019

Last Update

June 24 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Novo Nordisk Investigational Site

Glendale, California, United States, 91206